Xenetic Biosciences Statistics
Total Valuation
XBIO has a market cap or net worth of $5.92 million. The enterprise value is $1.80 million.
Important Dates
The last earnings date was Thursday, November 13, 2025, before market open.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
XBIO has 2.28 million shares outstanding. The number of shares has increased by 0.11% in one year.
| Current Share Class | 2.28M |
| Shares Outstanding | 2.28M |
| Shares Change (YoY) | +0.11% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 4.67% |
| Owned by Institutions (%) | 2.98% |
| Float | 1.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.40 |
| Forward PS | 4.40 |
| PB Ratio | 1.01 |
| P/TBV Ratio | 1.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.63 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.56
| Current Ratio | 4.56 |
| Quick Ratio | 3.71 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -57.43% and return on invested capital (ROIC) is -37.65%.
| Return on Equity (ROE) | -57.43% |
| Return on Assets (ROA) | -31.56% |
| Return on Invested Capital (ROIC) | -37.65% |
| Return on Capital Employed (ROCE) | -83.68% |
| Revenue Per Employee | $1.43M |
| Profits Per Employee | -$1.58M |
| Employee Count | 2 |
| Asset Turnover | 0.44 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.77% in the last 52 weeks. The beta is 2.39, so XBIO's price volatility has been higher than the market average.
| Beta (5Y) | 2.39 |
| 52-Week Price Change | -28.77% |
| 50-Day Moving Average | 3.71 |
| 200-Day Moving Average | 3.37 |
| Relative Strength Index (RSI) | 38.35 |
| Average Volume (20 Days) | 80,692 |
Short Selling Information
The latest short interest is 22,549, so 0.99% of the outstanding shares have been sold short.
| Short Interest | 22,549 |
| Short Previous Month | 62,406 |
| Short % of Shares Out | 0.99% |
| Short % of Float | 1.18% |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, XBIO had revenue of $2.86 million and -$3.16 million in losses. Loss per share was -$2.05.
| Revenue | 2.86M |
| Gross Profit | 2.86M |
| Operating Income | -3.31M |
| Pretax Income | -3.16M |
| Net Income | -3.16M |
| EBITDA | n/a |
| EBIT | -3.31M |
| Loss Per Share | -$2.05 |
Full Income StatementBalance Sheet
The company has $4.12 million in cash and n/a in debt, giving a net cash position of $4.12 million or $1.81 per share.
| Cash & Cash Equivalents | 4.12M |
| Total Debt | n/a |
| Net Cash | 4.12M |
| Net Cash Per Share | $1.81 |
| Equity (Book Value) | 3.96M |
| Book Value Per Share | 2.56 |
| Working Capital | 3.96M |
Full Balance SheetCash Flow
| Operating Cash Flow | -2.72M |
| Capital Expenditures | n/a |
| Free Cash Flow | -2.72M |
| FCF Per Share | -$1.19 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -115.80% and -110.40%.
| Gross Margin | 100.00% |
| Operating Margin | -115.80% |
| Pretax Margin | -110.40% |
| Profit Margin | -110.40% |
| EBITDA Margin | n/a |
| EBIT Margin | -115.80% |
| FCF Margin | n/a |
